Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Olga PaciosTranslational and Multidisciplinary Microbiology Research Group (MicroTM)-Microbiology Department, Biomedical Research Institute of A Coruña (INIBIC), A Coruña Hospital (CHUAC), University of A Coruña (UDC), 15006 A Coruña, Spain.ORCID 0000-0002-4476-856X
Soraya Herrera-EspejoInstitute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.ORCID 0000-0001-8019-0905
Lucía ArmánTranslational and Multidisciplinary Microbiology Research Group (MicroTM)-Microbiology Department, Biomedical Research Institute of A Coruña (INIBIC), A Coruña Hospital (CHUAC), University of A Coruña (UDC), 15006 A Coruña, Spain.
Clara Ibarguren-QuilesTranslational and Multidisciplinary Microbiology Research Group (MicroTM)-Microbiology Department, Biomedical Research Institute of A Coruña (INIBIC), A Coruña Hospital (CHUAC), University of A Coruña (UDC), 15006 A Coruña, Spain.
Lucía BlascoTranslational and Multidisciplinary Microbiology Research Group (MicroTM)-Microbiology Department, Biomedical Research Institute of A Coruña (INIBIC), A Coruña Hospital (CHUAC), University of A Coruña (UDC), 15006 A Coruña, Spain.ORCID 0000-0002-4039-4142
Inés BleriotTranslational and Multidisciplinary Microbiology Research Group (MicroTM)-Microbiology Department, Biomedical Research Institute of A Coruña (INIBIC), A Coruña Hospital (CHUAC), University of A Coruña (UDC), 15006 A Coruña, Spain.ORCID 0000-0002-1846-4693
Laura Fernández-GarcíaTranslational and Multidisciplinary Microbiology Research Group (MicroTM)-Microbiology Department, Biomedical Research Institute of A Coruña (INIBIC), A Coruña Hospital (CHUAC), University of A Coruña (UDC), 15006 A Coruña, Spain.ORCID 0000-0002-8531-6105
Concha Ortiz-CartagenaTranslational and Multidisciplinary Microbiology Research Group (MicroTM)-Microbiology Department, Biomedical Research Institute of A Coruña (INIBIC), A Coruña Hospital (CHUAC), University of A Coruña (UDC), 15006 A Coruña, Spain.
María PaniaguaInstitute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.
Antonio Barrio-PujanteTranslational and Multidisciplinary Microbiology Research Group (MicroTM)-Microbiology Department, Biomedical Research Institute of A Coruña (INIBIC), A Coruña Hospital (CHUAC), University of A Coruña (UDC), 15006 A Coruña, Spain.
Belén AracilMEPRAM, Project of Personalized Medicine against Antimicrobial Resistance, 28029 Madrid, Spain.
José Miguel CisnerosInstitute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.ORCID 0000-0001-5001-672X
María Eugenia Pachón-IbáñezInstitute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain.ORCID 0000-0001-7969-8162
María TomásTranslational and Multidisciplinary Microbiology Research Group (MicroTM)-Microbiology Department, Biomedical Research Institute of A Coruña (INIBIC), A Coruña Hospital (CHUAC), University of A Coruña (UDC), 15006 A Coruña, Spain.ORCID 0000-0003-4501-0387
Funding
IInstituto de Salud Carlos III (ISCIII) PI22/00323
6 · The paper itself
Abstract
The combination of several therapeutic strategies is often seen as a good way to decrease resistance rates, since bacteria can more easily overcome single-drug treatments than multi-drug ones. This strategy is especially attractive when several targets and subpopulations are affected, as it is the case of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Mitomycin C as an Anti-Persister Strategy against · full record | OpenQuestion